2. Signaling Pathways
  3. Metabolic Enzyme/Protease
  4. MAGL

MAGL

Monoacylglycerol lipase

MAGL

Related Products

PDF 0.44 MB

Monoacylglycerol lipase (MAGL) is a serine hydrolase that plays a crucial role catalysing the hydrolysis of monoglycerides into glycerol and fatty acids. MAGL links the endocannabinoid and eicosanoid systems together by degradation of the abundant endocannabinoid 2-arachidaoylglycerol into arachidonic acid, the precursor of prostaglandins and other inflammatory mediators.

MAGL plays a critical role in lipid signalling: i) it is the major enzyme that controls the levels of 2-AG, an important lipid with various neuroprotective effects; ii) inactivation of MAGL induces an elevation in brain levels of 2-AG and a reduction of AA, a key precursor of pro-inflammatory prostaglandins, resulting in the reduction of neuroinflammation; iii) MAGL regulates the levels of free fatty acids (FFAs) in aggressive cancer cells, and this MAGL-promoted fatty acid network drives a number of pro-tumorigenic signalling pathways. MAGL is emerging as a promising drug target for various diseases.

MAGL Related Products (67):

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-117722
    JW 618
    		Inhibitor
    JW 618 is a selective ABHD6 inhibitor, with IC50s of 38 and 13 nM for mouse and rat ABHD6.
    JW 618
  • HY-143263
    FAAH/MAGL-IN-1
    		Inhibitor
    FAAH/MAGL-IN-1 (compound SIH 3) is a potent FAAH and MAGL inhibitor with IC50s of 31 nM and 29 nM, respectively. FAAH/MAGL-IN-1 has the potential for the research of neuropathic pain.
    FAAH/MAGL-IN-1
  • HY-103463
    SA57
    		Inhibitor ≥99.0%
    SA57 is a potent, selective FAAH inhibitor with IC50s of 3.2 nM and 1.9 nM for mouse and human FAAH. SA57 also inhibits the 2-arachidonoylglycerol hydrolases MAGL (IC50s of 410 nM and 1.4 μM for mouse and human MAGL) and mouse α/β-hydrolase domain-containing protein 6 (mABHD6; IC50 of 850 nM), but not other brain serine hydrolases.
    SA57
  • HY-157038
    MAGL-IN-8
    		Inhibitor
    MAGL-IN-8 (compound 13) is a reversible monoacylglycerol lipase (MAGL) inhibitor, with an IC50 of 2.5 ± 0.4 nM for hMAGL.
    MAGL-IN-8
  • HY-144375
    Monoacylglycerol lipase inhibitor 1
    		Inhibitor
    Monoacylglycerol lipase inhibitor 1 is a potent monoacylglycerol lipase inhibitor (compound 13).
    Monoacylglycerol lipase inhibitor 1
  • HY-143264
    FAAH/MAGL-IN-2
    		Inhibitor
    FAAH/MAGL-IN-2 is a potent, reversible, orally active, and cross the blood-brain barrier FAAH and MAGL inhibitor with IC50s of 11 nM and 36 nM (Kis of 28 nM and 60 nM), respectively . FAAH/MAGL-IN-2 has the potential to research neuropathic pain without causing locomotion impairment.
    FAAH/MAGL-IN-2
  • HY-110178
    WWL123
    		Inhibitor ≥98.0%
    WWL123, a carbamate-based compound, is a potent and selective ABHD6 inhibitor. WWL123 can be used for research of inflammation, metabolic disorders (obesity and type II diabetes mellitus) and epilepsy.
    WWL123
  • HY-120171
    DH-376
    		Inhibitor
    DH-376 is a potent diacylglycerol lipase inhibitor with pIC50 values of 8.6 and 8.9 for ABHD6 and DAGLα, respectively. DH-376 prevents fasting-induced refeeding of mice. DH-376 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
    DH-376
  • HY-116793
    Dimepiperate
    Dimepiperate (MY 93) is a thiocarbamate (TC) pesticide. Dimepiperate has potential off-targets effect for the inhibition of ABHD6.
    Dimepiperate
  • HY-146341
    FAAH-IN-5
    		Inhibitor
    FAAH-IN-5 (Compound 7) is a relative selective, irreversible fatty acid amide hydrolase (FAAH) inhibitor with an IC50 of 10.5 nM. FAAH-IN-5 shows low PAMPA (Parallel Artificial Membrane Permeability Assay) permeability.
    FAAH-IN-5
  • HY-118653
    SAR629
    SAR629 is a potent monoglyceride lipase (MGL) covalent inhibitor. SAR629 also inhibits 2-Arachidonoylglycerol (2-AG) degradation.
    SAR629
  • HY-124314
    LEI-106
    		Inhibitor
    LEI-106 is a potent, dual sn-1-Diacylglycerol lipase α (DAGL-α)/ABHD6 inhibitor with an IC50 of 18 nM for DAGL-α and a Ki of 0.8 μM for ABHD6. LEI-106 inhibits the hydrolysis of [14C]-sn-1-oleoyl-2-arachidonoyl-glycerol, the natural substrate of DAGL-α, with a Ki of 0.7 μM.
    LEI-106
  • HY-162304
    MAGL-IN-14
    		Inhibitor
    MAGL-IN-14 (compound 2) is a potent inhibitor of MAGL, with IC50 of 0.00289 μM and 0.002 μM in HEK293 and PC3 cells, respectively.
    MAGL-IN-14
  • HY-168032
    MAGL-IN-18
    		Inhibitor
    MAGL-IN-18 (compound 118) is a potent Monoacylglycerol lipase (MAGL) inhibitor with an IC50 of 0.03 nM.
    MAGL-IN-18
  • HY-145945
    MAGL-IN-6
    		Inhibitor
    MAGL-IN-6 is a potent MAGL inhibitor with an IC50 of 4.71 nM. MAGL-IN-6 can be used for neurological disorders research (WO2020065613A1; example 234).
    MAGL-IN-6
  • HY-163202
    MAGL-IN-13
    		Inhibitor
    MAGL-IN-13 (compound (3R, 4S) - 5v) is a selective, irreversible inhibitor for MAGL,with IC50 values of 0.026, 0.021 and 0.24 nM for mMAGL, hMAGL and rMAGL, respectively. MAGL-IN-13 can penetrant blood brain barrier. .
    MAGL-IN-13
  • HY-162305
    MAGL-IN-15
    		Inhibitor
    MAGL-IN-15 (Compound 6) is a MAGL inhibitor that can be used in the research of diseases and disorders related to the regulation of endocannabinoid system signaling activities.
    MAGL-IN-15
  • HY-103339
    VDM11
    		Inhibitor
    VDM11 is a potent and selective anandamide membrane transporter (AMT) inhibitor. VDM11 inhibits FAAH and MAGL and may act as an alternative FAAH substrate.
    VDM11
  • HY-12332R
    JW 642 (Standard)
    		Inhibitor
    JW 642 (Standard) is the analytical standard of JW 642. This product is intended for research and analytical applications.
    JW 642 (Standard)
  • HY-157042
    MAGL-IN-11
    		Inhibitor
    MAGL-IN-11 (compound 29) is a selective and reversible MAGL inhibitor. MAGL-IN-11 has the potential to study inflammation, cancer and antioxidants.
    MAGL-IN-11